Analyst Conference Summaries

Biotechnology Investor Aids

Acceleron Pharma
XLRN

conference date: May 6, 2021 @ 2:00 PM Pacific Time

Acceleron: Neutral On Stock Price Gains [April 5, 2021, Seeking Alpha]

Acceleron Reblozyl For Beta Thalassemia Is Just The Beginning [March 4, 2020, Seeking Alpha]

Acceleron Heads To Commercial Success [December 2, 2019, Seeking Alpha]

FDA Approves Reblozyl (Luspatercept) for Beta Thalassemia [November 8, 2019, Celgene Press Release]

Analyst Conference Notes by William P. Meyers
2021
Acceleron
XLRN
Q1 2021
     
May 6, 2021      
2020
Acceleron
XLRN
Q1 2020
Acceleron
XLRN
Q2 2020
Acceleron
XLRN
Q3 2020
Acceleron
XLRN
Q4 2020
May 11, 2020 Aug. 6, 2020 Nov. 5, 2020 Feb. 25, 2021
2019
Acceleron
XLRN
Q1 2019
Acceleron
XLRN
Q2 2019
Acceleron
XLRN
Q3 2019
Acceleron
XLRN
Q4 2019
May 9, 2019 Aug. 5, 2019 Nov. 6, 2019 Feb. 27, 2020
2018
Acceleron
XLRN
Q4 2018
May 8, 2018
Aug. 2, 2018
Oct. 30, 2018
Feb. 27, 2019
2017
May 8, 2017
August 3, 2017
Nov. 7, 2017
Feb. 27, 2018
2016
05/05/2016
08/04/2016
11/03/2016
03/01/2017
2015
 

 
11/04/2015 
02/25/2016

Acceleron: Luspatercept New Data Is A Buy Signal [June 7, 2018, Seeking Alpha]

Acceleron Pharma is a development stage biotechnology company.

Acceleron Pharma web site


 

Search

More Analyst Conference Pages:

 AGEN
 AGIO
 ALNY
 ALXN
 AMAT
 AMGN
 APRE
 ARWR
 BIIB
 BMY
 CLDX
 CLSN
 EPZM
 GILD
 GLYC
 ILMN
 INCY
 INO
 IONS
 ISRG
 MCHP
 MRNA
 PLX
 REGN
 RNA
 SAGE
 SGEN
 SYRS
 TTPH
 VBLT
 VSTM
 XLRN

       

Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but it is possible. This is investment journalism, not financial advice.

Copyright 2021 William P. Meyers